Esperion Therapeutics Inc (ESPR)

Apr 25, 2025

Esperion Reveals Next-Gen Cholesterol Treatment Strategy: FDA-Approved Non-Statin Leader Updates Growth Plans - Stock Titan

Apr 25, 2025

Apr 25, 2025

Esperion to Participate in The Citizens Life Sciences Conference - GlobeNewswire

Apr 25, 2025

Apr 24, 2025

Esperion unveils novel PSC treatment candidates By Investing.com - Investing.com Canada

Apr 24, 2025

Apr 24, 2025

Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics - Zacks Investment Research

Apr 24, 2025

Apr 24, 2025

Esperion (ESPR) Advances ACLY Inhibitors for Rare Liver Disease Treatment | ESPR Stock News - GuruFocus

Apr 24, 2025

Apr 24, 2025

Esperion unveils novel PSC treatment candidates - Investing.com

Apr 24, 2025

Apr 24, 2025

Esperion Unveils Promising Research Supporting Lead - GlobeNewswire

Apr 24, 2025

Apr 24, 2025

New PSC Liver Disease Treatment Breakthrough: Promising Data Reveals Path to $1B Market Opportunity - Stock Titan

Apr 24, 2025

Apr 23, 2025

Esperion to Report First Quarter 2025 Financial Results on May 6 - The Manila Times

Apr 23, 2025

Apr 23, 2025

Esperion Q1 2025 Earnings Preview: What's Next for this FDA-Approved Cardiovascular Drug Maker? - Stock Titan

Apr 23, 2025

Apr 22, 2025

Esperion Therapeutics (ESPR) Loses -51.03% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance

Apr 22, 2025

Apr 21, 2025

Esperion Therapeutics Inc (ESPR) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ... By GuruFocus - Investing.com Canada

Apr 21, 2025

Apr 21, 2025

Esperion stock hits 52-week low at $0.91 amid challenges By Investing.com - Investing.com South Africa

Apr 21, 2025

Apr 21, 2025

Esperion stock hits 52-week low at $0.91 amid challenges - Investing.com

Apr 21, 2025

Apr 11, 2025

Esperion Therapeutics (ESPR) Faces Downward Earnings Estimate Re - GuruFocus

Apr 11, 2025

Apr 10, 2025

Esperion to Host R&D Day to Highlight Cardiometabolic Pipeline Innovation and Next-Generation Therapeutics on April 24, 2025 - The Manila Times

Apr 10, 2025

Apr 10, 2025

Esperion to Host R&D Day to Highlight Cardiometabolic - GlobeNewswire

Apr 10, 2025

Apr 10, 2025

Major Pipeline Expansion: Esperion to Reveal New Disease Target at R&D Day - Stock Titan

Apr 10, 2025

Apr 07, 2025

Esperion stock hits 52-week low at $1.17 amid challenges By Investing.com - Investing.com South Africa

Apr 07, 2025

Apr 07, 2025

Esperion stock hits 52-week low at $1.17 amid challenges - Investing.com Australia

Apr 07, 2025

Apr 07, 2025

Esperion at Needham Conference: Strategic Growth and Expansion By Investing.com - Investing.com Canada

Apr 07, 2025

Apr 05, 2025

Esperion announces CCO Eric Warren to step down - Investing.com Australia

Apr 05, 2025

Apr 04, 2025

Esperion announces CCO Eric Warren to step down By Investing.com - Investing.com Canada

Apr 04, 2025

Apr 03, 2025

Esperion Therapeutics (ESPR) Down 15.8% Since Last Earnings Report: Can It Rebound? - Yahoo Finance

Apr 03, 2025

Apr 02, 2025

Diametric Capital LP Sells 312,829 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) - MarketBeat

Apr 02, 2025

Apr 01, 2025

Esperion Appoints Robert E. Hoffman as New Director - TipRanks

Apr 01, 2025

Apr 01, 2025

Esperion appoints Robert Hoffman to board of directors - Investing.com

Apr 01, 2025

Apr 01, 2025

Esperion appoints Robert Hoffman to board of directors By Investing.com - Investing.com UK

Apr 01, 2025

Apr 01, 2025

Esperion Appoints Robert E. Hoffman to Board of Directors - GlobeNewswire

Apr 01, 2025

Apr 01, 2025

Strategic Board Shake-up: Esperion Lands Former Kintara CEO Hoffman as Director - Stock Titan

Apr 01, 2025

Mar 31, 2025

Esperion stock hits 52-week low at $1.46 amid challenges By Investing.com - Investing.com South Africa

Mar 31, 2025

Mar 31, 2025

Esperion stock hits 52-week low at $1.46 amid challenges - Investing.com

Mar 31, 2025

Mar 24, 2025

Esperion to Participate in 24th Annual Needham Virtual Healthcare Conference - GlobeNewswire

Mar 24, 2025

Mar 24, 2025

Exclusive: Esperion Reveals Next-Gen Drug Pipeline at Major Healthcare Conference - Stock Titan

Mar 24, 2025

Mar 21, 2025

BB Biotech AG Reduces Stake in Esperion Therapeutics Inc - GuruFocus

Mar 21, 2025

Mar 21, 2025

ESPR to Study Bempedoic Acid in Pediatric Familial Hypercholesterolemia - Nasdaq

Mar 21, 2025

Mar 20, 2025

Esperion Therapeutics Says FDA Clears Phase 3 Bempedoic Acid Trial in Hypercholesterolemia - MarketScreener

Mar 20, 2025

Mar 20, 2025

Esperion Aligns with U.S. Food and Drug Administration to Initiate Phase 3 Clinical Trials of Bempedoic Acid in Pediatric Heterozygous and Homozygous Familial Hypercholesterolemia - The Manila Times

Mar 20, 2025

Mar 20, 2025

Esperion Aligns with U.S. Food and Drug Administration to - GlobeNewswire

Mar 20, 2025

Mar 20, 2025

Esperion Therapeutics (ESPR) Aligns with U.S. Food and Drug Administration to Initiate Phase 3 Clinical Trials of Bempedoic Acid - StreetInsider.com

Mar 20, 2025

Mar 20, 2025

FDA Backs Esperion's Breakthrough Move into Pediatric Cholesterol Treatment - Stock Titan

Mar 20, 2025

Mar 20, 2025

Esperion Therapeutics chief commercial officer sells $3,617 in stock By Investing.com - Investing.com India

Mar 20, 2025

Mar 19, 2025

Esperion Therapeutics CFO sells $5,242 in stock By Investing.com - Investing.com Australia

Mar 19, 2025

Mar 19, 2025

Esperion Therapeutics CEO Koenig sells $19,622 in stock By Investing.com - Investing.com South Africa

Mar 19, 2025

Mar 19, 2025

Esperion Therapeutics CEO Koenig sells $19,622 in stock - Investing.com

Mar 19, 2025

Mar 19, 2025

Esperion Therapeutics CFO sells $5,242 in stock - Investing.com India

Mar 19, 2025

Mar 19, 2025

Esperion Therapeutics chief commercial officer sells $3,617 in stock - Investing.com

Mar 19, 2025